Mechanisms of islet amyloidosis toxicity in type 2 diabetes

FEBS Letters

Volumn 587, Issue 8, 2013, Pages 1119-1127

  Abedini, Andisheh ^a   Schmidt, Ann Marie ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Amylin; Amyloidosis; Islet amyloid polypeptide; Metabolic disease; Type 2 diabetes

Indexed keywords

AMYLIN; AMYLIN DERIVATIVE; INSULIN; LEPTIN; PRAMLINTIDE;

AMINO ACID SEQUENCE; AMYLOIDOSIS; BODY WEIGHT; CELL METABOLISM; CYTOTOXICITY; DIABETES MELLITUS; ENERGY METABOLISM; GLUCOSE BLOOD LEVEL; GRAFT FAILURE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; ISLET AMYLOIDOSIS; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW; SATIETY;

AMINO ACID SEQUENCE; AMYLOIDOSIS; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN-SECRETING CELLS; ISLET AMYLOID POLYPEPTIDE; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; MUTATION; RECEPTORS, ISLET AMYLOID POLYPEPTIDE;

EID: 84876021115     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2013.01.017     Document Type: Review

References (125)

1. J.D. Sipe Amyloidosis Crit. Rev. Clin. Lab. Sci. 31 1994 325 354
2. D.J. Selkoe Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases Nat. Cell Biol. 6 2004 1054 1061
3. F. Chiti, and C.M. Dobson Protein misfolding, functional amyloid, and human disease Annu. Rev. Biochem. 75 2006 333 366
4. A. Mitraki Protein aggregation: from inclusion bodies to amyloid and biomaterials Adv. Protein Chem. Struct. Biol. 79 2010 89 125
5. S.M. Johnson, S. Connelly, C. Fearns, E.T. Powers, and J.W. Kelly The transthyretin amyloidoses: fom delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug J. Mol. Biol. 42 2012 185 203
6. K.H. Johnson, T.D. O'Brien, C. Betsholtz, and P. Westermark Islet amyloid, islet-amyloid polypeptide, and diabetes mellitus N. Engl. J. Med. 321 1989 513 518
7. M.D. Kirkitadze, G. Bitan, and D.B. Teplow Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: the emerging role of oligomers J. Neurosci. Res. 69 2002 567 577
8. R. Kayed, E. Head, J.L. Thompson, T.M. McIntire, S.C. Milton, C.W. Cotman, and C.G. Glable Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis Science 300 2003 486 489
9. T. Sanke, G.I. Bell, C. Sample, A.H. Rubenstein, and D.F. Steiner An islet amyloid peptide is derived from an 89-amino acid precursor by proteolytic processing J. Biol. Chem. 263 1988 17243 17246
10. L. Marzban, G. Trigo-Gonzalez, and C.B. Verchere Processing of pro-islet amyloid polypeptide in the constitutive and regulated secretory pathways of beta cells Mol. Endocrinol. 19 2005 2154 2163
11. S.E. Kahn, D.A. Dalessio, M.W. Schwartz, W.Y. Fujimoto, J.W. Ensinck, G.J. Taborsky, and D. Porte Evidence of cosecretion of islet amyloid polypeptide and insulin by beta-cells Diabetes 39 1990 634 638
12. E.B. Dunkelberger, L.E. Buchanan, P. Marek, P. Cao, D.P. Raleigh, and M.T. Zanni Deamidation accelerates amyloid formation and alters amylin fiber structure J. Am. Chem. Soc. 134 2012 12658 12667
13. P. Westermark, U. Engstrom, K.H. Johnson, G.T. Westermark, and C. Betsholtz Islet amyloid polypeptide-pinpointing amino-acid-residues linked to amyloid fibril formation Proc. Natl. Acad. Sci. USA 87 1990 5036 5040
14. C. Betsholtz, L. Christmansson, U. Engstrom, F. Rorsman, V. Svensson, K.H. Johnson, and P. Westermark Sequence divergence in a specific region of islet amyloid polypeptide (IAPP) explains differences in islet amyloid formation between species FEBS Lett. 251 1989 261 264
15. A. Abedini, F.L. Meng, and D.P. Raleigh A single-point mutation converts the highly amyloidogenic human islet amyloid polypeptide into a potent fibrillization inhibitor J. Am. Chem. Soc. 129 2007 11300 11301
16. F.L. Meng, D.P. Raleigh, and A. Abedini Combination of kinetically selected inhibitors in trans leads to highly effective inhibition of amyloid formation J. Am. Chem. Soc. 132 2010 14340 14342
17. L.M. Yan, M. Tatarek-Nossol, A. Velkova, A. Kazantzis, and A. Kapurniotu Design of a mimic of nonamyloidogenic and bioactive human islet amyloid polypeptide (IAPP) as nanomolar affinity inhibitor of IAPP cytotoxic fibrillogenesis Proc. Natl. Acad. Sci. USA 103 2006 2046 2051
18. S. Sakagashira, H.J. Hiddinga, K. Tateishi, T. Sanke, T. Hanabusa, K. Nanjo, and N.L. Eberhardt S20G mutant amylin exhibits increased in vitro amyloidogenicity and increased intracellular cytotoxicity compared to wild-type amylin Am. J. Pathol. 157 2000 2101 2109
19. P. Cao, L.H. Tu, A. Abedini, O. Levsh, R. Akter, V. Patsalo, A.M. Schmidt, and D.P. Raleigh Sensitivity of amyloid formation by human islet amyloid polypeptide to mutations at residue 20 J. Mol. Biol. 421 2012 282 295
20. A. Abedini, and D.P. Raleigh Destabilization of human IAPP amyloid fibrils by proline mutations outside of the putative amyloidogenic domain: is there a critical amyloidogenic domain in human IAPP? J. Mol. Biol. 355 2006 274 281
21. B.W. Koo, J.A. Hebda, and A.D. Miranker Amide inequivalence in the fibrillar assembly of islet amyloid polypeptide Protein Eng. Des. Sel. 21 2008 147 154
22. A. Fox, T. Snollaerts, C. Errecart Casanova, A. Calciano, L.A. Nogaj, and D.A. Moffet Selection for nonamyloidogenic mutants of islet amyloid polypeptide (IAPP) identifies an extended region for amyloidogenicity Biochemistry 49 2010 7783 7789
23. L.M. McLatchie, N.J. Fraser, M.J. Main, A. Wise, J. Brown, N. Thompson, R. Solari, M.G. Lee, and S.M. Foord RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor Nature 393 1998 333 339
24. R. Muff, N. Buhlmann, J.A. Fischer, and W. Born Amylin receptor is revealed following co-transfection of a calcitonin receptor with receptor activity modifying proteins-1or-3 Endocrinology 140 1999 2924 2927
25. D.R. Poyner, P.M. Sexton, I. Marshall, D.M. Smith, R. Quirion, W. Born, R. Roman Muff, J.A. Fischer, and S.M. Foord International Union of Pharmacology. XXXII: the mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors Pharmacol. Rev. 54 2002 233 246
26. T.A. Lutz The role of amylin in the control of energy homeostasis Am. J. Physiol. Regul. Integr. Comp. Physiol. 298 2010 R1475 R1484
27. P. Westermark, A. Andersson, and G.T. Westermark Islet amyloid polypeptide, islet amyloid, and diabetes mellitus Physiol. Rev. 91 2011 795 826
28. J. Montane, A. Klimek-Abercrombie, K.J. Potter, C. Westwell-Roper, and C.B. Verchere Metabolic stress, IAPP and islet amyloid Diab. Obes. Metab. 14 2012 68 77
29. T.A. Lutz Control of energy homeostasis by amylin Cell. Mol. Life Sci. 69 2012 1947 1965
30. Z.L. Wang, W.M. Bennet, M.A. Ghatei, P.G. Byfield, D.M. Smith, and S.R. Bloom Influence of islet amyloid polypeptide and the 8-37 fragment of islet amyloid polypeptide on insulin release from perifused rat islets Diabetes 42 1993 330 335
31. A. Young Inhibition of insulin secretion Adv. Pharmacol. 52 2005 173 192
32. T. Riediger, M. Rauch, and H.A. Schmid Actions of amylin on subfornical organ neurons and on drinking behaviour in rats Am. J. Physiol. Regul. Integr. Comp. Physiol. 276 1999 R514 R521
33. R.D. Reidelberger, A.C. Haver, and U. Arnelo Amylin receptor blockade stimulates food intake and body adiposity in rats Am. J. Physiol. Regul. Integr. Comp. Physiol. 287 2004 R568 R574
34. C.S. Potes, and T.A. Lutz Brainstem mechanisms of amylin-induced anorexia Physiol. Behav. 100 2010 511 518
35. J.L. Trevaskis, D.G. Parkes, and J.D. Roth Insights into amylin-leptin synergy Trends Endocrinol. Metab. 21 2010 473 479
36. E.L. Opie The relation of diabetes mellitus to lesions of the pancreas. Hyaline degeneration of the islands of Langerhans J. Exp. Med. 5 1901 527 540
37. P. Westermark, C. Wernstedt, E. Wilander, D.W. Hayden, T.D. Obrien, and K.H. Johnson Amyloid fibrils in human insulinoma and islets of langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells Proc. Natl. Acad. Sci. USA 84 1987 3881 3885
38. G.J.S. Cooper, A.C. Willis, A. Clark, R.C. Turner, R.B. Sim, and K.B.M. Reid Purification and characterization of a peptide from amyloid-rich pancreases of type-2 diabetic-patients Proc. Natl. Acad. Sci. USA 84 1987 8628 8632
39. F.M. Ashcroft, and P. Rosman Diabetes mellitus and the cell: the last ten years Cell 148 2012 1160 1171
40. W. El-Assaad, J. Buteau, M.L. Peyot, C. Nolan, R. Roduit, S. Hardy, E. Joly, G. Dbaibo, L. Rosenberg, and M. Prentki Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death Endocrinology 144 2003 4154 4163
41. L.R. Brunham, J.K. Kruit, M.R. Hayden, and C.B. Verchere Cholesterol in beta-cell dysfunction: the emerging connection between HDL cholesterol and type 2 diabetes Curr. Diab. Rep. 10 2010 55 60
42. M.Y. Donath, and S.E. Shoelson Type 2 diabetes as an inflammatory disease Nat. Rev. Immunol. 11 2011 98 107
43. V. Poitout, and R.P. Robertson Minireview: secondary beta-cell failure in type 2 diabetes-a convergence of glucotoxicity and lipotoxicity Endocrinology 143 2002 339 342
44. P. Westermark, D.L. Eizirik, D.G. Pipeleers, C. Hellerstrom, and A. Andersson Rapid deposition of amyloid in human islets transplanted into nude mice Diabetologia 38 1995 543 549
45. J. Udayasankar, K. Kodama, R.L. Hull, S. Zraika, K. Aston-Mourney, S.L. Subramanian, J. Tong, M.V. Faulenbach, J. Vidal, and S.E. Kahn Amyloid formation results in recurrence of hyperglycaemia following transplantation of human IAPP transgenic mouse islets Diabetologia 52 2009 145 153
46. G.T. Westermark, P. Westermark, C. Berne, O. Korsgren, and N.N.C.I. Transpla Widespread amyloid deposition in transplanted human pancreatic islets N. Engl. J. Med. 359 2008 977 979
47. K.J. Potter, A. Abedini, P. Marek, A.M. Klimek, S. Butterworth, M. Driscoll, R. Baker, M.R. Nilsson, G.L. Warnock, J. Oberholzer, S. Bertera, M. Trucco, G.S. Korbutt, P.E. Fraser, D.P. Raleigh, and C.B. Verchere Islet amyloid deposition limits the viability of human islet grafts but not porcine islet grafts Proc. Natl. Acad. Sci. USA 107 2010 4305 4310
48. R.E. Ratner, R. Dickey, and M. Fineman Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in Type-1 diabetes mellitus: a 1-year, randomized controlled trial Diab. Med. 21 2004 1204 1212
49. I.D. Young, L. Ailles, S. Narindrasorasak, R. Tan, and R. Kisilevsky Localization of the basement membrane heparan sulfate proteoglycan in islet amyloid deposits in type II diabetes mellitus Arch. Pathol. Lab. Med. 116 1992 951 954
50. K. Conde-Knape Heparan sulfate proteoglycans in experimental models of diabetes: a role for perlecan in diabetes complications Diab. Metab. Res. Rev. 17 2001 412 421
51. J. Vidal, C.B. Verchere, S. Andrikopoulos, F. Wang, R.L. Hull, M. Cnop, K.L. Olin, R.C. LeBoeuf, K.D. O'Brien, A. Chait, and S.E. Kahn The effect of apolipoprotein E deficiency on islet amyloid deposition in human islet amyloid polypeptide transgenic mice Diabetologia 46 2003 71 79
52. M.B. Pepys, D.R. Booth, W.L. Hutchinson, J.R. Gallimore, P.M. Collins, and E. Hohenester Amyloid P component. A critical review Amyloid 4 1997 274 295
53. K.R. Bales, T. Verina, R.C. Dodel, Y.S. Du, L. Altstiel, M. Bender, P. Hyslop, E.M. Johnstone, S.P. Little, D.J. Cummins, P. Piccardo, B. Ghetti, and S.M. Paul Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition Nat. Genet. 17 1997 263 264
54. S. Jha, S.M. Patil, J. Gibson, C.E. Nelson, N.N. Alder, and A.T. Alexandrescu Mechanism of amylin fibrillization enhancement by heparin J. Biol. Chem. 286 2011 22894 22904
55. K. Park, and C.B. Verchere Identification of a heparin binding domain in the N-terminal cleavage site of pro-islet amyloid polypeptide-implications for islet amyloid formation J. Biol. Chem. 276 2001 16611 16616
56. J.F. Paulsson, and G.T. Westermark Aberrant processing of human proislet amyloid polypeptide results in increased amyloid formation Diabetes 54 2005 2117 2125
57. 2-terminal processing of human proislet amyloid polypeptide by the prohormone convertase PC2 leads to amyloid formation and cell death Diabetes 55 2006 2192 2201
58. F. Meng, A. Abedini, B. Song, and D.P. Raleigh Amyloid formation by pro-islet amyloid polypeptide processing intermediates: examination of the role of protein heparan sulfate interactions and implications for islet amyloid formation in type 2 diabetes Biochemistry 46 2007 12091 12099
59. G.T. Westermark, and P. Westermark Localized amyloids important in diseases outside the brain-lessons from the islets of Langerhans and the thoracic aorta FEBS J. 278 2011 3918 3929
60. R.L. Hull, S. Zraika, J. Udayasankar, R. Kisilevsky, W.A. Szarek, T.N. Wight, and S.E. Kahn Inhibition of glycosaminoglycan synthesis and protein glycosylation with WAS-406 and azaserine result in reduced islet amyloid formation in vitro Am. J. Physiol. Cell Physiol. 293 2007 C1586 C1593
61. A. Abedini, and D.P. Raleigh The role of His-18 in amyloid formation by human islet amyloid polypeptide Biochemistry 44 2005 16284 16291
62. P.J. Marek, V. Patsalo, D.F. Green, and D.P. Raleigh Ionic strength effects on amyloid formation by amylin are a complicated interplay among Debye screening, ion selectivity, and hofmeister effects Biochemistry 51 2012 8478 8490
63. T. Gurlo, S. Ryazantsev, C.J. Huang, M.W. Yeh, H.A. Reber, O.J. Hines, T.D. O'Brien, C.G. Glabe, and P.C. Butler Evidence for proteotoxicity in beta cells in type 2 diabetes: toxic islet amyloid polypeptide oligomers form intracellularly in the secretory pathway Am. J. Pathol. 176 2010 861 869
64. K. Aston-Mourney, R.L. Hull, S. Zraika, J. Udayasankar, S.L. Subramanian, and S.E. Kahn Exendin-4 increases islet amyloid deposition but offsets the resultant beta cell toxicity in human islet amyloid polypeptide transgenic mouse islets Diabetologia 54 2011 1756 1765
65. S. Zraika, R.L. Hull, C.B. Verchere, A. Clark, K.J. Potter, P.E. Fraser, D.P. Raleigh, and S.E. Kahn Toxic oligomers and islet beta cell death: guilty by association or convicted by circumstantial evidence? Diabetologia 53 2010 1046 1056
66. D. Schubert, C. Behl, R. Lesley, A. Brack, R. Dargusch, and Y. Sagara Amyloid peptides are toxic via a common oxidative mechanism Proc. Natl. Acad. Sci. USA 92 1995 1989 1993
67. M.P. Mattson Degenerative and protective signaling mechanisms in the neurofibrillary pathology of AD Neurobiol. Aging 16 1995 447 457
68. T. Saitoh, K. Horsburgh, and E. Masliah Hyperactivation of signal transduction systems in Alzheimer's disease Ann. N.Y. Acad. Sci. 695 1993 34 41
69. J.M. Shoffner Oxidative phosphorylation defects and Alzheimer's disease Neurogenetics 1 1997 13 19
70. A.Y. Abramov, L. Canevari, and M.R. Duchen Calcium signals induced by amyloid-peptide and their consequences in neurons and astrocytes in culture Biochim. Biophys. Acta 1742 2004 81 87
71. P.S. Brookes, Y. Yoon, J.L. Robotham, M.W. Anders, and S.S. Sheu Calcium, ATP, and ROS: a mitochondrial love-hate triangle Am. J. Physiol. Cell Physiol. 287 2004 C817 C833
72. M. Hashimoto, E. Rockenstein, L. Crews, and E. Masliah Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases NeuroMol. Med. 4 2004 21 36
73. S. Mittal, and S. Ganesh Protein quality control mechanisms and neurodegenerative disorders: checks, balances and deadlocks Neurosci. Res. 68 2010 159 166
74. Y.J. Park, S. Lee, T.J. Kieffer, G.L. Warnock, N. Safikhan, M. Speck, Z. Hao, M. Woo, and L. Marzban Deletion of Fas protects islet beta cells from cytotoxic effects of human islet amyloid polypeptide Diabetologia 55 2012 1035 1047
75. M. Yaar, S. Zhai, P.F. Pilch, S.M. Doyle, P.B. Eisenhauer, R.E. Fine, and B.A. Gilchrest Binding of beta-amyloid to the p75 neurotrophin receptor induces apoptosis-a possible mechanism for Alzheimer's disease J. Clin. Invest. 100 1997 2333 2340
76. S.D. Yan, H. Zhu, A. Zhu, A. Golabek, A. Roher, C. Yu, C. Soto, A.M. Schmidt, D.M. Stern, and M. Kindy Receptor glycation dependent cell stress and amyloid accumulation in systemic amyloidosis Nat. Med. 6 2000 643 651
77. A.M. Schmidt, B. Sahagan, R.B. Nelson, J. Selmer, R. Rothlein, and J.M. Bell The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer's disease Curr. Opin. Invest. Drugs 10 2009 672 680
78. S.D. Yan, X. Chen, J. Fu, M. Chen, H.J. Zhu, A. Roher, T. Slattery, L. Zhao, M. Nagashima, J. Morser, A. Migheli, P. Nawroth, D. Stern, and A.M. Schmidt RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease Nature 382 1996 685 691
79. B. Ravikumar, C. Vacher, Z. Berger, J.E. Davies, S. Luo, and L.G. Oroz Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease Nat. Genet. 36 2004 585 595
80. T. Shintani, and D.J. Klionsky Autophagy in health and disease: a double edged sword Science 306 2004 990 995
81. A.M. Cataldo, D.J. Hamilton, J.L. Barnett, P.A. Paskevich, and R.A. Nixon Properties of the endosomal-lysosomal system in the human central nervous system: disturbances mark most neurons in populations at risk to degenerate in Alzheimer's disease J. Neurosci. 16 1996 186 199
82. P.P. Liberski, B. Sikorska, J. Bratosiewicz-Wasik, D.C. Gajdusek, and P. Brown Neuronal cell death in transmissible spongiform encephalopathies (prion diseases) revisited: from apoptosis to autophagy Int. J. Biochem. Cell Biol. 36 2004 2473 2490
83. P. Eikelenboom, C. Bate, W.A. Van Gool, J.J. Hoozemans, J.M. Rozemuller, and R. Veerhuis Neuroinflammation in Alzheimer's disease and prion disease GLIA 40 2002 232 239
84. P. Eikelenboom, and W.A. van Gool Neuroinflammatory perspectives on the two faces of Alzheimer's disease J. Neural Transm. 111 2004 281 294
85. P.L. McGeer, and E.G. McGeer Inflammation and neurodegeneration in Parkinson's disease Parkinsonism Relat. Disord. 10 1 2004 S3 S7
86. P.L. McGeer, S. Itagaki, B.E. Boyes, and E.G. McGeer Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains Neurology 38 1988 1285 1291
87. Y.C. Chung, H.W. Ko, and E. Bok The role of neuroinflammation on the pathogenesis of Parkinson's disease BMB Rep. 43 2010 225 232
88. A. MacHado, A.J. Herrera, and J.L. Venero Peripheral inflammation increases the damage in animal models of nigrostriatal dopaminergic neurodegeneration: possible implication in Parkinson's disease incidence Parkinson's disease 2011 2011 1 10 Article ID 393769
89. E.C. Hirsch Glial cells and Parkinson's disease J. Neurol. 247 Suppl. 2 2000 II58 II62
90. M.O. Fagarasan, and S. Efthimiopoulos Mechanism of amyloid beta-peptide (1-42) toxicity in PC12 cells Mol. Psychiatry 1 1996 398 403
91. B. Kaltschmidt, M. Uherek, B. Volk, P.A. Baeuerle, and C. Kaltschmidt Transcription factor NF-kappa B is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease Proc. Natl. Acad. Sci. USA 94 1997 2642 2647
92. S.L. Masters, and L.A.J. O'Neill Disease-associated amyloid and misfolded protein aggregates activate the inflammasome Trends Mol. Med. 17 2011 276 282
93. J. Hardy, and D.J. Selkoe The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics Science 297 2002 353 356
94. M.P. Lambert, A.K. Barlow, B.A. Chromy, C. Edwards, R. Freed, and M. Liosatos Diffusible, nonfibrillar ligands derived from A1-42 are potent central nervous system neurotoxins Proc. Natl. Acad. Sci. USA 95 1998 6448 6453
95. C.G. Glabe Common mechanisms of amyloid oligomer pathogenesis in degenerative disease Neurobiol. Aging 27 2006 570 575
96. M. Bucciantini, E. Giannoni, F. Chiti, F. Baroni, L. Formigli, J.S. Zurdo, N. Taddei, G. Ramponi, C.M. Dobson, and M. Stefani Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases Nature 416 2002 507 511
97. C. Haass Presenile because of presenilin: the presenilin genes and early onset Alzheimer's disease Curr. Opin. Neurol. 9 1996 254 259
98. E.L. Saafi, B. Konarkowska, S.P. Zhang, J. Kistler, and G.J.S. Cooper Ultrastructural evidence that apoptosis is the mechanism by which human amylin evokes death in rinm5f pancreatic islet beta-cells Cell Biol. Int. 25 2001 339 350
99. A.E. Butler, J. Janson, W.C. Soeller, and P.C. Butler Increased beta-cell apoptosis prevents adaptive increase in beta-cell mass in mouse model of type 2 diabetes-evidence for role of islet amyloid formation rather than direct action of amyloid Diabetes 52 2003 2304 2314
100. G.J.S. Cooper, J.F. Aitken, and S. Zhang Is type 2 diabetes an amyloidosis and does it really matter (to patients)? Diabetologia 53 2010 1011 1016
101. A.V. Matveyenko, and P.C. Butler Beta-cell deficit due to increased apoptosis in the human islet amyloid polypeptide transgenic (hip) rat recapitulates the metabolic defects present in type 2 diabetes Diabetes 55 2006 2106 2114
102. S. Zhang, J. Liu, M. Dragunow, and G.J. Cooper Fibrillogenic amylin evokes islet beta-cell apoptosis through linked activation of a caspase cascade and JNK1 J. Biol. Chem. 278 2003 52810 52819
103. S.L. Subramanian, R.L. Hull, S. Zraika, K. Aston-Mourney, J. Udayasankar, and S.E. Kahn CJun N-terminal kinase (JNK) activation mediates islet amyloid-induced beta cell apoptosis in cultured human islet amyloid polypeptide transgenic mouse islets Diabetologia 55 2012 166 174
104. A. Demuro, E. Mina, R. Kayed, S.C. Milton, I. Parker, and C.G. Glabe Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers J. Biol. Chem. 280 2005 17294 17300
105. J.R. Brender, S. Salamekh, and A. Ramamoorthy Membrane disruption and early events in the aggregation of the diabetes related peptide IAPP from a molecular perspective Acc. Chem. Res. 45 2012 454 462
106. J. Seeliger, K. Weise, N. Opitz, and R. Winter The effect of a beta on IAPP aggregation in the presence of an isolated beta-cell membrane J. Mol. Biol. 421 2012 348 363
107. S. Trikha, and A.M. Jeremic Clustering and internalization of toxic amylin oligomers in pancreatic cells require plasma membrane cholesterol J. Biol. Chem. 286 2011 36086 36097
108. S. Costes, C.J. Huang, T. Gurlo, M. Daval, A.V. Matveyenko, R.A. Rizza, A.E. Butler, and P.C. Butler Beta-cell dysfunctional ERAD/ubiquitin/proteasome system in type 2 diabetes mediated by islet amyloid polypeptide-induced UCH-L1 deficiency Diabetes 60 2011 227 238
109. S. Casas, R. Gomis, F.M. Gribble, J. Altirriba, S. Knuutila, and A. Novials Impairment of the ubiquitin-proteasome pathway is a downstream endoplasmic reticulum stress response induced by extracellular human islet amyloid polypeptide and contributes to pancreatic beta-cell apoptosis Diabetes 56 2007 2284 2294
110. J.F. Rivera, T. Gurlo, M. Daval, C.J. Huang, A.V. Matveyenko, P.C. Butler, and S. Costes Human-IAPP disrupts the autophagy/lysosomal pathway in pancreatic beta-cells: protective role of p62 positive cytoplasmic inclusions Cell Death Differ. 18 2011 415 426
111. R.L. Hull, S. Zraika, J. Udayasankar, K. Aston-Mourney, S.L. Subramanian, and S.E. Kahn Amyloid formation in human IAPP transgenic mouse islets and pancreas, and human pancreas, is not associated with endoplasmic reticulum stress Diabetologia 52 2009 1102 1111
112. S.L. Masters Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes Nat. Immunol. 11 2010 897 904
113. S. Zraika, R.L. Hull, J. Udayasankar, K. Aston-Mourney, S.L. Subramanian, R. Kisilevsky, W.A. Szarek, and S.E. Kahn Oxidative stress is induced by islet amyloid formation and time-dependently mediates amyloid-induced beta cell apoptosis Diabetologia 52 2009 626 635
114. C. Westwell-Roper, D.L. Dai, G. Soukhatcheva, K.J. Potter, N. van Rooijen, J.A. Ehses, and C.B. Verchere IL-1 blockade attenuates islet amyloid polypeptide-induced proinflammatory cytokine release and pancreatic islet graft dysfunction J. Immunol. 187 2011 2755 2765
115. S. Morita, S. Sakagashira, Y. Shimajiri, N.L. Eberhardt, T. Kondo, T. Kondo, and T. Sanke Autophagy protects against human islet amyloid polypeptide-associated apoptosis J. Diab. Invest. 2 2011 48 55
116. C.J. Huang, C.Y. Lin, L. Haataja, T. Gurlo, A.E. Butler, R.A. Rizza, and P.C. Butler High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes Diabetes 56 2007 2016 2027
117. T. Gurlo, S. Ryazantsev, C.J. Huang, M.W. Yeh, H.A. Reber, O.J. Hines, T.D. O'Brien, C.G. Glabe, and P.C. Butler Evidence for proteotoxicity in beta cells in type 2 diabetes: toxic islet amyloid polypeptide oligomers form intracellularly in the secretory pathway Am. J. Pathol. 176 2010 861 869
118. E. Law, S. Lu, T.J. Kieffer, G.L. Warnock, Z. Ao, M. Woo, and L. Marzban Differences between amyloid toxicity in alpha and beta cells in human and mouse islets and the role of caspase-3 Diabetologia 53 2010 1415 1427
119. F.D. Allard, A.E. Walalce, and G.J. Greenbaum Emerging therapies: going beyond insulin in treating individuals with type-I diabetes mellitus Curr. Opin. Endocrinol. Diab. 12 2005 303 308
120. J.D. Roth, B.L. Roland, R.L. Cole, J.L. Trevaskis, C. Weyer, J.E. Koda, C.M. Anderson, D.G. Parkes, and A.D. Baron Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies Proc. Natl. Acad. Sci. USA 105 2008 7257 7262
121. J.L. Trevaskis, D.G. Parkes, and J.D. Roth Insights into amylin-leptin synergy Trends Endocrinol. Metab. 21 2010 473 479
122. R. Seth, W.D. Knight, and J.M. Overton Combined amylin-leptin treatment lowers blood pressure and adiposity in lean and obese rats Int. J. Obesity 35 2011 1183 1192
123. D.L. Morris, and L. Rui Recent advances in understanding leptin signaling and leptin resistance Am. J. Physiol. Endocrinol. Metab. 297 2009 E1247 E1259
124. J.D. Roth Anti obesity effects of the beta-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression Endocrinology 147 2006 5855 5864
125. H.S. Moon, J.P. Chamberland, and C.S. Mantzoros Amylin and leptin activate overlapping signaling pathways in an additive manner in mouse GT1-7 hypothalamic, C2C12 muscle and AML12 liver cell lines Diabetologia 55 2012 215 225